• You are not being treated in Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Israel, Italy, Poland, Portugal, Romania, Spain, Switzerland, Turkey, Ukraine;
• You show presence of central nervous system (CNS) lymphoma (either primary or secondary) or leptomeningeal disease;
• You have a significant uncontrolled medical condition such as renal, hepatic, hematological, GI, endocrine, pulmonary, neurological, cerebral, or psychiatric disease;
• You have a history of stroke or intracranial hemorrhage within 6 months of this trial;
• You have an HIV infection;
• You have a hepatitis B (HBV) or hepatitis C (HCV) infection: Participants positive for HBV surface antigen or HBV core antibody will be eligible if they are negative for HBV DNA; you could be considered for prophylactic antiviral therapy. If you are positive for HCV antibody, you could be eligible if you are negative for HCV RNA;
• You have a cardiac disease such as unstable angina, acute myocardial infarction, or cardiac conduction issues, within 6 months before the start of this trial;
• You have congestive heart failure or uncontrolled arrhythmia;
• You are unable to swallow and retain oral medication, you have malabsorption syndrome, a disease significantly affecting GI function, a total resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

If you meet all of these conditions you might be allowed to enter the screening process.